Browsing by Author "Huinink, W. W. Ten Bokkel"
Now showing items 1-4 of 4
-
Article
Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study
Sternberg, Cora N.; Huinink, W. W. Ten Bokkel; Smyth, J. F.; Bruntsch, V.; Dirix, L. Y.; Pavlidis, Nicholas; Franklin, H. R.; Wanders, S.; Bail, N. Le; Kaye, Stanley B. (1994)Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were ...
-
Article
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Huinink, W. W. Ten Bokkel; Pavlidis, Nicholas; Sorio, R.; Gamucci, T.; Wolff, I.; Velde, A. Te; Lan, J.; Verweij, J. (1996)In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, ...
-
Article
Multicentre phase II pharmacological evaluation of rhizoxin
McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...
-
Article
Phase II clinical trials with rhizoxin in breast cancer and melanoma
Hanauske, A. R.; Catimel, G.; Aamdal, S.; Huinink, W. W. Ten Bokkel; Paridaens, R.; Pavlidis, Nicholas; Kaye, Stanley B.; Velde, A. Te; Wanders, J.; Verweij, J. (1996)Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose ...